# Syngene International share price today (Syngene International Ltd, NSE: SYNGENE)

> Syngene International share price today: ₹406.60 at the NSE close on 3 November 2026, down 37.5% in a year. Syngene International (NSE: SYNGENE) is worth ₹16,401 crore, trades at a P/E of 61.8 and has closed between ₹347.40 and ₹658.40 over the past 52 weeks. > Syngene International Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. SYNGENE · Pharma - API & CRAMS · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/syngene-international-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Getting worse, from the last 12 quarters
- Price: ₹406.60 (−37.5% in a year)
- P/E: 61.8× (higher than 78% of the last 8.3 years)
- Revenue (Sep 2026): ₹833 Cr (−8.6% on a year ago)
- Profit (Sep 2026): ₹32.0 Cr (−52.2% on a year ago)
- Operating margin: 18.0% (−4.0 points on a year ago)
- ROCE: 10%, FY26
- ROIC: 7.7%, against a 12.0% cost of capital: −4.3 points

The main question: domestic institutions moved +11.8 percentage points over 8 quarters while the business went the other way. ## What is the Syngene International share price today? Syngene International Ltd's share price was ₹406.60 at the close on 3 November 2026. It has been falling for 89 weeks. That is 8.8% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹347 and ₹658, and at that close it sat 19% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 2 weeks in a row. Over the last 11 years the share price moved +103% while the NIFTY 500 moved +251%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Syngene International this quarter? Three changes stood out: foreign funds (FIIs) cut their stake for 8 quarters in a row, indian funds and insurers (DIIs) raised their stake for 14 quarters in a row and profit down on a year earlier for 5 quarters in a row. 1. Foreign funds (FIIs) cut their stake for 8 quarters in a row From 20.7% to 10.1% of the company by the September 2026 quarter. 2. Indian funds and insurers (DIIs) raised their stake for 14 quarters in a row From 10.7% to 29.3% of the company by the September 2026 quarter. 3. Profit down on a year earlier for 5 quarters in a row In the September 2026 quarter profit was ₹32 crore, -52.2% on a year earlier. Why: Profit has fallen for five quarters, and the latest drop came because a high-margin product, Librela, was no longer in the sales mix, so fixed costs were spread over less profitable work. Next results: check whether the Zoetis batches are delivered on time, since that is the planned second-half rebound. From the earnings call on 28 Oct 2026. ## What are Syngene International's latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), Syngene International reported revenue of ₹833 crore, down 8.6% from ₹911 crore a year earlier, and a profit of ₹32.0 crore, down 52.2% from ₹67.0 crore. ### Syngene International results: July to September 2026 against a year earlier

| Measure | July to September 2026 | July to September 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹833 crore | ₹911 crore | −8.6% |
| Profit | ₹32.0 crore | ₹67.0 crore | −52.2% |
| Earnings per share | ₹0.80 | ₹1.67 | −52.1% |
| Operating margin | 18.0% | 22.0% | −4.0 points |

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Syngene International's management discussed these results on a call held on 28 October 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.)

## What is the Syngene International share price history? Syngene International closed at ₹406.60 on 3 November 2026, down 37.5% from ₹650.10 a year earlier (31 October 2025) and down 26.5% over five years. Its highest weekly close since March 2016 was ₹940.80 on 29 November 2024. ### Syngene International share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹366.85 | +10.8% |
| 1 month ago · 1 Oct 2026 | ₹361.30 | +12.5% |
| 6 months ago · 30 Apr 2026 | ₹467.65 | −13.1% |
| 1 year ago · 31 Oct 2025 | ₹650.10 | −37.5% |
| 3 years ago · 3 Nov 2023 | ₹693.60 | −41.4% |
| 5 years ago · 4 Nov 2021 | ₹553.00 | −26.5% |
| 10 years ago · 4 Nov 2016 | ₹271.43 | +49.8% |
| Earliest weekly close in our records · 11 Mar 2016 | ₹199.95 | +103.4% |
| Highest weekly close since March 2016 · 29 Nov 2024 | ₹940.80 | −56.8% |
| Lowest weekly close since March 2016 · 13 Apr 2016 | ₹178.35 | +128.0% |
| 52-week high (weekly close) · 2 Jan 2026 | ₹658.40 | −38.2% |
| 52-week low (weekly close) · 9 Oct 2026 | ₹347.40 | +17.0% |

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (562 weekly closes from 11 March 2016 to 3 November 2026.)

## What is the latest news on Syngene International? 3 Nov 2026: Syngene International closed at ₹406.60, up 10.8% on the week and up 12.5% on the month. 28 Oct 2026: Syngene International held its results call for July to September 2026. Management guided: Bayview drug substance manufacturing to begin in FY28 after India process work in FY27. ### Earlier

- Results for July to September 2026: Revenue down 8.6% and profit down 52.2% on a year earlier. - 25 Jun 2026: ex-date for a dividend of ₹1.25 a share, record date 26 Jun 2026. ## What dividend does Syngene International pay? Syngene International paid ₹1.25 a share in regular dividends in the 12 months to 4 November 2026 (1 payment), a yield of 0.31% at the ₹406.60 close on 3 November 2026. The last was a dividend of ₹1.25 a share, ex-date 25 June 2026. ### Syngene International dividends since 1 April 2021

| Ex-date | Dividend per share | Type | Record date |
| --- | --- | --- | --- |
| 25 Jun 2026 | ₹1.25 | Dividend | 26 Jun 2026 |
| 27 Jun 2025 | ₹1.25 | Dividend | same day |
| 28 Jun 2024 | ₹1.25 | Dividend | same day |
| 30 Jun 2023 | ₹1.25 | Dividend + Special | same day |
| 30 Jun 2022 | ₹1 | Dividend + Special | 1 Jul 2022 |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 4 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Syngene International Ltd paid out 16% of its profit as dividends in FY26, and it paid a dividend in 7 of its last 9 reported years. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Syngene International management say on the latest results call? On the call for July to September 2026, held on 28 October 2026, Syngene International's management guided: Bayview drug substance manufacturing to begin in FY28 after India process work in FY27. > “We offer a dual manufacturing strategy, which many CMOs cannot do. Even Samsung does not have a facility in the US.”
> Siddharth Mittal, on the call for July to September 2026

### What management guided

- Bayview commercial volumes only post product approval, a couple years out; first approvals planned in H2 CY28 best case. - Biocon Park biologics batches for Zoetis to deliver in January to March 2027 back-end-loaded; no other-customer work there until next fiscal. - Operating margin in mid-20s excluding hedge drag, guidance maintained. - Similar hedge losses in second half on forwards for large dedicated contract, then pivot to options after expiry. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijoristack.ai/concall/transcript/5715-28-Oct-2026.pdf). (From the call for July to September 2026, 28 October 2026.)

## What to watch in Syngene International's next results? When Syngene International reports October to December 2026, these are the 3 checks that show whether the story is still on course. First: Back-end-loaded Zoetis batches from Biocon Park facility deliver on time - confirms second-half rebound plank. - What to check (from the call)
- Back-end-loaded Zoetis batches from Biocon Park facility deliver on time - confirms second-half rebound plank. - Second-half hedge drag on dedicated forwards prints at flagged similar level - tests ex-hedge margin defence. - New client additions and molecule progressions from discovery to development disclosed - validates fee-for-service pivot. ## Which stock lists is Syngene International on? Syngene International is on 2 of our India lists: Small & mid cap stocks and Pharma stocks. - [Small & mid cap stocks Size rank in India: 401](https://www.sectoralpha.in/small-cap-stocks-india)
- [Pharma stocks Market value (₹ crore): 16669.76707226223](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Syngene International profitable? Syngene International Ltd earned ₹32.0 Cr of net profit in the Sep 2026 quarter, −52.2% on the same quarter a year earlier. Full-year FY26 profit was ₹317 Cr. Over 8 years profit has grown 0.5% a year on average. That is 3.8% of the quarter's revenue. The same quarter a year earlier earned ₹67.0 Cr. 1 of the last 12 reported quarters were loss-making. For the full year, FY26 profit was ₹317 Cr (−36.1% on the year before). Why profit moved: revenue changed −8.6% on a year earlier and the margin moved −4.0 percentage points. Sales did the work while the margin got thinner. On average over the last four quarters, profit changed −67.5% and revenue −6.4%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Syngene International make, and is it growing? Syngene International Ltd reported ₹833 Cr of revenue in the Sep 2026 quarter, −8.6% on the same quarter a year earlier. Over 8 years it has grown 12.8% a year on average. The last full year, FY26, came in at ₹3,739 Cr. The last four reported quarters add to ₹3,522 Cr. FY26 revenue was ₹3,739 Cr, +2.7% on the year before. Recent pace: the last four quarters grew −6.4% on average, against 12.8% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew −6.0%, against +1.0% a year over the last 8 quarters (rolling over); profit over the last 12 months grew −60.3%, against −37.9% a year (rolling over). ## How much of every ₹100 of sales does Syngene International keep? Syngene International Ltd's operating margin was 18.0% in the Sep 2026 quarter, 4.0 percentage points lower than the same quarter a year ago. Across 9 years it has been between 25.0% and 33.0%. The latest quarter is below every full year in that period. Why the margin moved: operating margin changed −4.2 percentage points on the year while gross margin changed +2.3 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Syngene International's profit turning into cash? Over the last 3 years, 236% of Syngene International Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹915 Cr of operating cash against ₹317 Cr of profit. After ₹431 Cr of spending on assets, ₹484 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 236% of profit came in as cash: the cash cycle got 15 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: the bigger use of cash is spending on new assets, at 1.9× depreciation over three years. The next section checks what that spending is building. ## Where does Syngene International's cash go? Syngene International Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was −32 days in FY26, up from −47 days in FY21. It spent ₹2,514 Cr on assets over the last 3 years. Customers take 50 days to pay, and stock sits for 56 days on average. At FY26 sales of ₹3,739 Cr, each day of that cycle ties up about ₹10.2 Cr, so roughly −₹328 Cr is tied up in the business at any time. FY26: customers took 50 days to pay and stock sat for 56 days, about 1.8 months of sales sitting as stock, for a full cycle of −32 days, longer than FY21's −47. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 56 days. Customers pay about 50 days after that. Suppliers are paid at 138 days. Together that makes the −32-day cycle. Spending on assets: ₹2,514 Cr over the last 3 years, against ₹1,312 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹1,046 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Syngene International's P/E ratio, and how does it compare with its own history? Syngene International Ltd's P/E is 61.8×, near the high end of its own history: higher than 78% of past readings. Its usual P/E (the middle reading) is 55.0×, over 8.3 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹4.62. Why the multiple is where it is: over the past year earnings per share moved −36.3% while the price moved −37.5%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 5 years the price moved −6.0% a year; about −8.1% a year came from earnings growth and about +2.1 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Syngene International business getting better or worse? Syngene International Ltd's business is getting worse. Revenue, profit and EPS growth are shrinking: revenue growth is −6.0% in the latest quarter, against +20.6% at its best in 12 quarters, with ROCE falling at 5.5%. This is based on 12 quarters of 4 measures. Why it matters: falling lines mean any ratio below that looks low should be read with that direction in mind. ## How much does Syngene International earn on its capital? Syngene International Ltd earned a ROCE of 10% in FY26. Its return on capital used (ROIC) is 4.3 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 8.5% net margin and 0.53× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 8.5% net margin × 0.53× asset turnover × 1.46× leverage (assets divided by equity) ≈ 6.6% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 7.7% − 12.0% = −4.3 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The 7.7% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 10.3%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Syngene International have too much debt? Syngene International Ltd has total debt of ₹507 Cr against shareholder equity of ₹4,859 Cr as of Sep 2026, so its debt is 0.10× its equity, which is very little. Year by year, that ratio went from 0.31 in FY22 to 0.09 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the Syngene International shareholding pattern? Domestic institutions raised their stake in Syngene International Ltd by 11.8 percentage points over 8 quarters, the biggest change among its owners. Domestic institutions now own 29.3% of the company. Foreign institutions moved −10.6 points over the same period, to 10.1%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Domestic institutions: +11.8 points over 8 quarters, to 29.3%; Foreign institutions: −10.6 points over 8 quarters, to 10.1%; Promoters: −2.1 points over 8 quarters, to 52.6%. Why the owners changed: foreign institutions moved −10.6 points and domestic institutions +11.8 points over 8 quarters, while promoters moved −2.1 points. One group of institutions took over shares from the other; it is not a change of mind by the people running the company. ## How far is Syngene International from balance-sheet trouble? For Syngene International Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Syngene International rank in its industry? 27.8 out of 100, rank 22 of 24 in Pharma - API & CRAMS, with 100% of the evidence available. Syngene International Ltd scores 27.8 out of 100 against the 24 companies it is compared with in Pharma - API & CRAMS, ranking 22. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 5.1 + 10.1 + 7.6 + 5 = 27.8. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Syngene International compared with? Syngene International ranks 22 of 24 Pharma - API & CRAMS companies on the 4-Factor Sector Score, with 27.8 out of 100. 1. [Neuland Laboratories Ltd](https://www.sectoralpha.in/stocks/neuland-laboratories-ltd) NEULANDLAB · leader · Most evidence points up · 96% evidence 76.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 32.3/35 · Revenue 78.3% · Profit 100% · Operating margin change 23 points · 88% evidence Capital efficiency 22.9/25 · ROCE 26.5% · Operating margin 35% · 100% evidence Valuation 14.1/20 · P/E 50.8× · PEG 1.04 · 100% evidence Relative strength 6.7/20 · Lead over its industry -7.8% · Lead over NIFTY 500 20.3% · 1 year 19.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 32.3 + 22.9 + 14.1 + 6.7 = 76 · What this means: Earnings are strong; relative strength in its sector is -7.8% and the one-year return is 19.6%. 2. [Acutaas Chemicals Ltd](https://www.sectoralpha.in/stocks/acutaas-chemicals-ltd) ACUTAAS · turning · Most evidence points up · 67% evidence 73.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.3/35 · Revenue 45.4% · Profit 95.5% · Operating margin change 9 points · 95% evidence Capital efficiency 20.3/25 · ROCE 31.6% · Operating margin 40% · 76% evidence Valuation 10.2/20 · P/E 74.6× · PEG n/a · 50% evidence Relative strength 12.1/20 · Lead over its industry n/a · Lead over NIFTY 500 59.6% · 1 year 131.7% · 25% evidence · 2 of 9 weeks ahead Exact sum: 31.3 + 20.3 + 10.2 + 12.1 = 73.9 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Laurus Labs Ltd](https://www.sectoralpha.in/stocks/laurus-labs-ltd) LAURUSLABS · leader · Most evidence points up · 93% evidence 71.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.9/35 · Revenue 23% · Profit 95.3% · Operating margin change 10 points · 100% evidence Capital efficiency 17.3/25 · ROCE 17.8% · Operating margin 34% · 100% evidence Valuation 5.8/20 · P/E 97× · PEG 2.98 · 65% evidence Relative strength 17.0/20 · Lead over its industry 42.3% · Lead over NIFTY 500 82.8% · 1 year 152.2% · 100% evidence · 12 of 12 weeks ahead Exact sum: 30.9 + 17.3 + 5.8 + 17 = 71 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 4. [Gland Pharma Ltd](https://www.sectoralpha.in/stocks/gland-pharma-ltd) GLAND · leader · Most evidence points up · 96% evidence 69.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.0/35 · Revenue 17.6% · Profit 46.4% · Operating margin change 3 points · 88% evidence Capital efficiency 16.0/25 · ROCE 15.1% · Operating margin 27% · 100% evidence Valuation 12.1/20 · P/E 44.6× · PEG 1.45 · 100% evidence Relative strength 16.8/20 · Lead over its industry 15.1% · Lead over NIFTY 500 49.3% · 1 year 60.5% · 100% evidence · 12 of 12 weeks ahead Exact sum: 25 + 16 + 12.1 + 16.8 = 69.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [IOL Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/iol-chemicals-pharmaceuticals-ltd) IOLCP · leader · Most evidence points up · 100% evidence 69.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.1/35 · Revenue 26.7% · Profit 75% · Operating margin change 4 points · 100% evidence Capital efficiency 12.8/25 · ROCE 11.3% · Operating margin 14% · 100% evidence Valuation 13.9/20 · P/E 24.6× · PEG 0.66 · 100% evidence Relative strength 13.9/20 · Lead over its industry 21.6% · Lead over NIFTY 500 53.8% · 1 year 92.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 29.1 + 12.8 + 13.9 + 13.9 = 69.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Shilpa Medicare Ltd](https://www.sectoralpha.in/stocks/shilpa-medicare-ltd) SHILPAMED · leader · Most evidence points up · 89% evidence 67.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.4/35 · Revenue 28% · Profit 100% · Operating margin change 1 points · 88% evidence Capital efficiency 10.8/25 · ROCE 10.9% · Operating margin 29% · 100% evidence Valuation 9.9/20 · P/E 65.7× · PEG 1.73 · 65% evidence Relative strength 19.9/20 · Lead over its industry 47.2% · Lead over NIFTY 500 84.2% · 1 year 170.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 26.4 + 10.8 + 9.9 + 19.9 = 67 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Morepen Laboratories Ltd](https://www.sectoralpha.in/stocks/morepen-laboratories-ltd) MOREPENLAB · leader · Evidence leans up · 85% evidence 62.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.8/35 · Revenue 30.1% · Profit 90.9% · Operating margin change 9 points · 100% evidence Capital efficiency 9.3/25 · ROCE 8.1% · Operating margin 16% · 100% evidence Valuation 8.5/20 · P/E 32.9× · PEG 2.14 · 100% evidence Relative strength 12.5/20 · Lead over its industry n/a · Lead over NIFTY 500 94.5% · 1 year 139% · 25% evidence · 12 of 12 weeks ahead Exact sum: 31.8 + 9.3 + 8.5 + 12.5 = 62.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Divis Laboratories Ltd](https://www.sectoralpha.in/stocks/divis-laboratories-ltd) DIVISLAB · leader · Evidence leans up · 96% evidence 61.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.7/35 · Revenue 16.4% · Profit 26.8% · Operating margin change 11 points · 88% evidence Capital efficiency 18.6/25 · ROCE 22% · Operating margin 41% · 100% evidence Valuation 2.6/20 · P/E 87.1× · PEG 3.45 · 100% evidence Relative strength 15.5/20 · Lead over its industry 9.2% · Lead over NIFTY 500 43.1% · 1 year 45.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24.7 + 18.6 + 2.6 + 15.5 = 61.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 9. [Granules India Ltd](https://www.sectoralpha.in/stocks/granules-india-ltd) GRANULES · turning · Evidence leans up · 96% evidence 57.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.3/35 · Revenue 24.8% · Profit 38.1% · Operating margin change 3 points · 88% evidence Capital efficiency 16.2/25 · ROCE 15.5% · Operating margin 23% · 100% evidence Valuation 10.2/20 · P/E 35.2× · PEG 1.29 · 100% evidence Relative strength 6.7/20 · Lead over its industry -5.2% · Lead over NIFTY 500 24.2% · 1 year 48.5% · 100% evidence · 7 of 12 weeks ahead Exact sum: 24.3 + 16.2 + 10.2 + 6.7 = 57.4 · What this means: Earnings are strong; relative strength in its sector is -5.2% and the one-year return is 48.5%. 10. [Sai Life Sciences Ltd](https://www.sectoralpha.in/stocks/sai-life-sciences-ltd) SAILIFE · leader · Evidence leans up · 89% evidence 57.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.7/35 · Revenue 17.6% · Profit 48% · Operating margin change 3 points · 88% evidence Capital efficiency 17.0/25 · ROCE 19.6% · Operating margin 27% · 100% evidence Valuation 4.8/20 · P/E 90× · PEG 3.63 · 65% evidence Relative strength 13.8/20 · Lead over its industry 9.9% · Lead over NIFTY 500 42.9% · 1 year 69.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21.7 + 17 + 4.8 + 13.8 = 57.3 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 11. [SMS Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/sms-pharmaceuticals-ltd) SMSPHARMA · breaking out · Evidence leans up · 96% evidence 55.8 out of 100 Growth Capital Valuation Relative
12. [Blue Jet Healthcare Ltd](https://www.sectoralpha.in/stocks/blue-jet-healthcare-ltd) BLUEJET · quiet · Evidence leans up · 81% evidence 52.7 out of 100 Growth Capital Valuation Relative
13. [Solara Active Pharma Sciences Ltd](https://www.sectoralpha.in/stocks/solara-active-pharma-sciences-ltd) SOLARA · breaking out · Evidence leans down · 74% evidence 49.5 out of 100 Growth Capital Valuation Relative
14. [Windlas Biotech Ltd](https://www.sectoralpha.in/stocks/windlas-biotech-ltd) WINDLAS · leader · Evidence leans down · 81% evidence 47.6 out of 100 Growth Capital Valuation Relative
15. [Anthem Biosciences Ltd](https://www.sectoralpha.in/stocks/anthem-biosciences-ltd) ANTHEM · leader · Evidence leans down · 89% evidence 46.7 out of 100 Growth Capital Valuation Relative
16. [Piramal Pharma Ltd](https://www.sectoralpha.in/stocks/piramal-pharma-ltd) PPLPHARMA · leader · Evidence leans down · 71% evidence 44.6 out of 100 Growth Capital Valuation Relative
17. [Supriya Lifescience Ltd](https://www.sectoralpha.in/stocks/supriya-lifescience-ltd) SUPRIYA · breaking out · Evidence leans down · 96% evidence 43.7 out of 100 Growth Capital Valuation Relative
18. [Concord Biotech Ltd](https://www.sectoralpha.in/stocks/concord-biotech-ltd) CONCORDBIO · quiet · Evidence leans down · 85% evidence 40.8 out of 100 Growth Capital Valuation Relative
19. [Jubilant Pharmova Ltd](https://www.sectoralpha.in/stocks/jubilant-pharmova-ltd) JUBLPHARMA · turning · Most evidence points down · 86% evidence 30.3 out of 100 Growth Capital Valuation Relative
20. [Hikal Ltd](https://www.sectoralpha.in/stocks/hikal-ltd) HIKAL · turning · Most evidence points down · 78% evidence 29.7 out of 100 Growth Capital Valuation Relative
21. [OneSource Specialty Pharma Ltd](https://www.sectoralpha.in/stocks/onesource-specialty-pharma-ltd) ONESOURCE · turning · Most evidence points down · 83% evidence 29.2 out of 100 Growth Capital Valuation Relative
22. Syngene International Ltd this page SYNGENE · turning · Most evidence points down · 100% evidence 27.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 5.1/35 · Revenue -6% · Profit -60.3% · Operating margin change -4 points · 100% evidence Capital efficiency 10.1/25 · ROCE 10% · Operating margin 18% · 100% evidence Valuation 7.6/20 · P/E 61.2× · PEG 7.87 · 100% evidence Relative strength 5.0/20 · Lead over its industry -33.4% · Lead over NIFTY 500 -9.2% · 1 year -38.1% · 100% evidence · 1 of 12 weeks ahead Exact sum: 5.1 + 10.1 + 7.6 + 5 = 27.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 23. [Cohance Lifesciences Ltd](https://www.sectoralpha.in/stocks/cohance-lifesciences-ltd) COHANCE · breaking out · Most evidence points down · 78% evidence 27.1 out of 100 Growth Capital Valuation Relative
24. [Dishman Carbogen Amcis Ltd](https://www.sectoralpha.in/stocks/dishman-carbogen-amcis-ltd) DCAL · basing · Most evidence points down · 64% evidence 27.0 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - API & CRAMS](https://www.sectoralpha.in/sectors/pharma-api-crams), all 24 compared on one page. ## Which companies are close to Syngene International in size? Syngene International is the 13th largest of 24 Pharma - API & CRAMS companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Shilpa Medicare, OneSource Specialty Pharma and Cohance Lifesciences. Just below it: Jubilant Pharmova, Concord Biotech and Blue Jet Healthcare. ### Pharma - API & CRAMS companies close in size

1. [Shilpa Medicare Ltd](https://www.sectoralpha.in/stocks/shilpa-medicare-ltd) ₹18,690 crore
2. [OneSource Specialty Pharma Ltd](https://www.sectoralpha.in/stocks/onesource-specialty-pharma-ltd) ₹17,924 crore
3. [Cohance Lifesciences Ltd](https://www.sectoralpha.in/stocks/cohance-lifesciences-ltd) ₹16,999 crore
4. Syngene International Ltd ₹16,256 crore
5. [Jubilant Pharmova Ltd](https://www.sectoralpha.in/stocks/jubilant-pharmova-ltd) ₹14,716 crore
6. [Concord Biotech Ltd](https://www.sectoralpha.in/stocks/concord-biotech-ltd) ₹13,031 crore
7. [Blue Jet Healthcare Ltd](https://www.sectoralpha.in/stocks/blue-jet-healthcare-ltd) ₹9,550 crore

[All 24 Pharma - API & CRAMS companies, largest first](https://www.sectoralpha.in/sectors/pharma-api-crams#all-companies)

### Companies close in size in other industries

1. [Nazara Technologies Ltd](https://www.sectoralpha.in/stocks/nazara-technologies-ltd) ₹16,294 crore · Entertainment & Media
2. [Ratnamani Metals & Tubes Ltd](https://www.sectoralpha.in/stocks/ratnamani-metals-tubes-ltd) ₹16,256 crore · Stainless Steel
3. Syngene International Ltd ₹16,256 crore
4. [Computer Age Management Services Ltd](https://www.sectoralpha.in/stocks/computer-age-management-services-ltd) ₹16,243 crore · Finance - Capital Markets - RTA
5. [Garware Hi Tech Films Ltd](https://www.sectoralpha.in/stocks/garware-hi-tech-films-ltd) ₹16,203 crore · Packaging - Films

## What else do people ask about Syngene International? ### What is Syngene International's share price today? Syngene International Ltd's share price is ₹406.60, −37.5% over the past year. The whole company is worth ₹16,401 Cr on the market. In the last 52 weeks it traded between ₹347 to ₹658; today it is 19% of the way up from the low, 8.8% below its 200-day average (as of 3 November 2026). ### What were Syngene International's latest quarterly results? Syngene International Ltd reported revenue of ₹833 Cr and net profit of ₹32.0 Cr for the Sep 2026 quarter. Revenue fell 8.6% and profit fell 52.2% compared with a year earlier. Earnings per share were ₹0.80. The operating margin was 18.0%, 4.0 percentage points lower than a year earlier (as of 3 November 2026). ### What is Syngene International's market cap? Syngene International Ltd's market capitalisation is ₹16,401 Cr at a share price of ₹406.60. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Syngene International performing? Syngene International Ltd's share price has been falling for 89 weeks. In its latest quarter, revenue fell 8.6% and profit fell 52.2% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 2 weeks running (as of 3 November 2026). ### Will Syngene International's share price go up? This page does not forecast Syngene International Ltd's share price. What it shows instead: the share price is ₹406.60, and it has been falling for 89 weeks. Its P/E of 61.8× is higher than 78% of its own last 8 years (as of 3 November 2026). ### Does Syngene International have too much debt? No, Syngene International Ltd has little debt: its debt is 0.09× its equity, and its operating profit is 19 times its interest bill. FY26 borrowings were ₹458 Cr against equity of ₹4,839 Cr. So the returns on this page come from the business, not borrowed money (as of 3 November 2026). ### Where is Syngene International in its business cycle? Syngene International Ltd's FY26 operating margin was 25.0%, against a 9-year range of 25.0% to 33.0%: the low end of its own range, which is often where recoveries start. The latest quarter was 18.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Syngene International story? The main question: domestic institutions moved +11.8 percentage points over 8 quarters while the business went the other way. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Syngene International a stock worth studying right now? What the numbers show: Syngene International Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: whether the owners’ moves turn back in line with the business. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a Syngene International share price forecast for 2026? What management itself guided: Bayview drug substance manufacturing to begin in FY28 after India process work in FY27. ## Lists

- Small & mid cap stocks: https://www.sectoralpha.in/small-cap-stocks-india
- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.